ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of chagas’ disease.
Nenhuma Miniatura disponível
Data
2023
Autores
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Immunization with the Amastigote Surface Protein-2 (ASP-2) and Trans-sialidase (TS) antigens either in the form of recombinant
protein, encoded in plasmids or human adenovirus 5 (hAd5) confers robust protection against various lineages of Trypanosoma
cruzi. Herein we generated a chimeric protein containing the most immunogenic regions for T and B cells from TS and ASP-2
(TRASP) and evaluated its immunogenicity in comparison with our standard protocol of heterologous prime-boost using plasmids
and hAd5. Mice immunized with TRASP protein associated to Poly-ICLC (Hiltonol) were highly resistant to challenge with T. cruzi,
showing a large decrease in tissue parasitism, parasitemia and no lethality. This protection lasted for at least 3 months after the last
boost of immunization, being equivalent to the protection induced by DNA/hAd5 protocol. TRASP induced high levels of T. cruzispecific antibodies and IFNγ-producing T cells and protection was primarily mediated by CD8+ T cells and IFN-γ. We also evaluated
the toxicity, immunogenicity, and efficacy of TRASP and DNA/hAd5 formulations in dogs. Mild collateral effects were detected at
the site of vaccine inoculation. While the chimeric protein associated with Poly-ICLC induced high levels of antibodies and CD4+ T
cell responses, the DNA/hAd5 induced no antibodies, but a strong CD8+ T cell response. Immunization with either vaccine
protected dogs against challenge with T. cruzi. Despite the similar efficacy, we conclude that moving ahead with TRASP together
with Hiltonol is advantageous over the DNA/hAd5 vaccine due to pre-existing immunity to the adenovirus vector, as well as the
cost-benefit for development and large-scale production.
Descrição
Palavras-chave
Citação
CASTRO, J. T. de et al. ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of chagas’ disease. Vaccines, v. 8, artigo 81, maio 2023. Disponível em: <https://www.nature.com/articles/s41541-023-00676-0>. Acesso em: 01 ago. 2023.